CI
CLVS

Cowen Inc’s Clovis Oncology, Inc. CLVS Stock Holding History

Cowen Inc’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-4,500
Closed -$132K – 542
2018
Q3 		$132K Buy
+4,500
New +$174K 0.01% 284
2017
Q3 		– Sell
-2,800
Closed -$262K – 339
2017
Q2 		$262K Buy
2,800
+1,300
+87% +$79.5K 0.01% 255
2017
Q1 		$96K Buy
+1,500
New +$91.2K ﹤0.01% 219

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Cowen Inc's CLVS Position: Q4 2018 in Review

Cowen Inc sold out of Clovis Oncology, Inc. (CLVS) in Q4 2018, closing a stake of 4,500 shares — an estimated $132K sold.

Cowen Inc first reported a position in CLVS in Q1 2017 and held it in 3 quarters. The position peaked at $262K in Q2 2017. 165 funds tracked by Wall St. Rank hold CLVS as of Q4 2018.

  • Cowen Inc reported no remaining Clovis Oncology, Inc. position as of Q4 2018 after selling out during the quarter.
  • Cowen Inc sold 4,500 Clovis Oncology, Inc. shares in Q4 2018, an estimated $132K.
  • Cowen Inc first reported a position in Clovis Oncology, Inc. in Q1 2017 and held it in 3 quarters.
  • Cowen Inc's Clovis Oncology, Inc. position peaked at $262K in Q2 2017.
  • 165 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2018.

Based on Cowen Inc's 13F filing for Q4 2018, filed 14 Feb 2019.